Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis

ABSTRACT Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. Methods: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Muscle & nerve Ročník 58; číslo 2; s. 261 - 269
Hlavní autoři:	Raheja, Radhika, Regev, Keren, Healy, Brian C., Mazzola, Maria Antonietta, Beynon, Vanessa, Von Glehn, Felipe, Paul, Anu, Diaz‐Cruz, Camilo, Gholipour, Taha, Glanz, Bonnie I., Kivisakk, Pia, Chitnis, Tanuja, Weiner, Howard L., Berry, James D., Gandhi, Roopali
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Wiley Subscription Services, Inc 01.08.2018
Témata:	Adult ALS Alzheimer Disease - blood Alzheimer Disease - physiopathology Alzheimer's disease Amyotrophic lateral sclerosis Amyotrophic Lateral Sclerosis - blood Amyotrophic Lateral Sclerosis - physiopathology Biomarkers Biomarkers - blood Cohort Studies Cross-Sectional Studies Diagnosis disease comparisons Disease control Disease Progression Female Gene Expression Regulation Humans longitudinal analysis Longitudinal Studies Male Medical prognosis microRNA MicroRNAs - blood Middle Aged miRNA Multiple sclerosis Multiple Sclerosis - blood Multiple Sclerosis - physiopathology Muscles Neurodegenerative diseases Parameter identification Patients Ribonucleic acid RNA serum ALS longitudinal analysis microRNA disease comparisons serum biomarkers
ISSN:	0148-639X, 1097-4598, 1097-4598
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	ABSTRACT Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. Methods: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross‐sectional and longitudinal cohorts of ALS patients with clinical parameters. Results: We identified 7 miRNAs (miR‐192‐5p, miR‐192‐3p, miR‐1, miR‐133a‐3p, miR‐133b, miR‐144‐5p, miR‐19a‐3p) that were upregulated and 6 miRNAs (miR‐320c, miR‐320a, let‐7d‐3p, miR‐425‐5p, miR‐320b, miR‐139‐5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR‐136‐3p, miR‐30b‐5p, miR‐331‐3p, miR‐496) correlated positively and change in 1 miRNA (miR‐2110) correlated negatively with changes in clinical parameters in longitudinal analysis. Discussion: Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58: 261–269, 2018
AbstractList	Introduction : Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. Methods : We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross‐sectional and longitudinal cohorts of ALS patients with clinical parameters. Results : We identified 7 miRNAs (miR‐192‐5p, miR‐192‐3p, miR‐1, miR‐133a‐3p, miR‐133b, miR‐144‐5p, miR‐19a‐3p) that were upregulated and 6 miRNAs (miR‐320c, miR‐320a, let‐7d‐3p, miR‐425‐5p, miR‐320b, miR‐139‐5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR‐136‐3p, miR‐30b‐5p, miR‐331‐3p, miR‐496) correlated positively and change in 1 miRNA (miR‐2110) correlated negatively with changes in clinical parameters in longitudinal analysis. Discussion : Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58 : 261–269, 2018 ABSTRACT Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. Methods: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross‐sectional and longitudinal cohorts of ALS patients with clinical parameters. Results: We identified 7 miRNAs (miR‐192‐5p, miR‐192‐3p, miR‐1, miR‐133a‐3p, miR‐133b, miR‐144‐5p, miR‐19a‐3p) that were upregulated and 6 miRNAs (miR‐320c, miR‐320a, let‐7d‐3p, miR‐425‐5p, miR‐320b, miR‐139‐5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR‐136‐3p, miR‐30b‐5p, miR‐331‐3p, miR‐496) correlated positively and change in 1 miRNA (miR‐2110) correlated negatively with changes in clinical parameters in longitudinal analysis. Discussion: Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58: 261–269, 2018 Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis.INTRODUCTIONAmyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis.We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross-sectional and longitudinal cohorts of ALS patients with clinical parameters.METHODSWe compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross-sectional and longitudinal cohorts of ALS patients with clinical parameters.We identified 7 miRNAs (miR-192-5p, miR-192-3p, miR-1, miR-133a-3p, miR-133b, miR-144-5p, miR-19a-3p) that were upregulated and 6 miRNAs (miR-320c, miR-320a, let-7d-3p, miR-425-5p, miR-320b, miR-139-5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR-136-3p, miR-30b-5p, miR-331-3p, miR-496) correlated positively and change in 1 miRNA (miR-2110) correlated negatively with changes in clinical parameters in longitudinal analysis.RESULTSWe identified 7 miRNAs (miR-192-5p, miR-192-3p, miR-1, miR-133a-3p, miR-133b, miR-144-5p, miR-19a-3p) that were upregulated and 6 miRNAs (miR-320c, miR-320a, let-7d-3p, miR-425-5p, miR-320b, miR-139-5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR-136-3p, miR-30b-5p, miR-331-3p, miR-496) correlated positively and change in 1 miRNA (miR-2110) correlated negatively with changes in clinical parameters in longitudinal analysis.Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58: 261-269, 2018.DISCUSSIONOur findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58: 261-269, 2018. Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross-sectional and longitudinal cohorts of ALS patients with clinical parameters. We identified 7 miRNAs (miR-192-5p, miR-192-3p, miR-1, miR-133a-3p, miR-133b, miR-144-5p, miR-19a-3p) that were upregulated and 6 miRNAs (miR-320c, miR-320a, let-7d-3p, miR-425-5p, miR-320b, miR-139-5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR-136-3p, miR-30b-5p, miR-331-3p, miR-496) correlated positively and change in 1 miRNA (miR-2110) correlated negatively with changes in clinical parameters in longitudinal analysis. Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58: 261-269, 2018. Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. Methods: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross‐sectional and longitudinal cohorts of ALS patients with clinical parameters. Results: We identified 7 miRNAs (miR‐192‐5p, miR‐192‐3p, miR‐1, miR‐133a‐3p, miR‐133b, miR‐144‐5p, miR‐19a‐3p) that were upregulated and 6 miRNAs (miR‐320c, miR‐320a, let‐7d‐3p, miR‐425‐5p, miR‐320b, miR‐139‐5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR‐136‐3p, miR‐30b‐5p, miR‐331‐3p, miR‐496) correlated positively and change in 1 miRNA (miR‐2110) correlated negatively with changes in clinical parameters in longitudinal analysis. Discussion: Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58: 261–269, 2018
Author	Glanz, Bonnie I. Von Glehn, Felipe Gholipour, Taha Gandhi, Roopali Beynon, Vanessa Chitnis, Tanuja Diaz‐Cruz, Camilo Raheja, Radhika Kivisakk, Pia Berry, James D. Weiner, Howard L. Healy, Brian C. Paul, Anu Regev, Keren Mazzola, Maria Antonietta
AuthorAffiliation	1 Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham & Women’s Hospital, Harvard Medical School, Boston, USA 2 Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 3 Tel Aviv Sourasky Medical Center, Neurology, Tel Aviv, Israel
AuthorAffiliation_xml	– name: 1 Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham & Women’s Hospital, Harvard Medical School, Boston, USA – name: 3 Tel Aviv Sourasky Medical Center, Neurology, Tel Aviv, Israel – name: 2 Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Author_xml	– sequence: 1 givenname: Radhika surname: Raheja fullname: Raheja, Radhika organization: Brigham and Women's Hospital, Harvard Medical School – sequence: 2 givenname: Keren surname: Regev fullname: Regev, Keren organization: Tel Aviv Sourasky Medical Center – sequence: 3 givenname: Brian C. surname: Healy fullname: Healy, Brian C. organization: Brigham and Women's Hospital, Harvard Medical School – sequence: 4 givenname: Maria Antonietta surname: Mazzola fullname: Mazzola, Maria Antonietta organization: Brigham and Women's Hospital, Harvard Medical School – sequence: 5 givenname: Vanessa surname: Beynon fullname: Beynon, Vanessa organization: Brigham and Women's Hospital, Harvard Medical School – sequence: 6 givenname: Felipe orcidid: 0000-0002-1004-7641 surname: Von Glehn fullname: Von Glehn, Felipe organization: Brigham and Women's Hospital, Harvard Medical School – sequence: 7 givenname: Anu surname: Paul fullname: Paul, Anu organization: Brigham and Women's Hospital, Harvard Medical School – sequence: 8 givenname: Camilo surname: Diaz‐Cruz fullname: Diaz‐Cruz, Camilo organization: Brigham and Women's Hospital, Harvard Medical School – sequence: 9 givenname: Taha surname: Gholipour fullname: Gholipour, Taha organization: Brigham and Women's Hospital, Harvard Medical School – sequence: 10 givenname: Bonnie I. surname: Glanz fullname: Glanz, Bonnie I. organization: Brigham and Women's Hospital, Harvard Medical School – sequence: 11 givenname: Pia surname: Kivisakk fullname: Kivisakk, Pia organization: Brigham and Women's Hospital, Harvard Medical School – sequence: 12 givenname: Tanuja orcidid: 0000-0002-9897-4422 surname: Chitnis fullname: Chitnis, Tanuja organization: Brigham and Women's Hospital, Harvard Medical School – sequence: 13 givenname: Howard L. surname: Weiner fullname: Weiner, Howard L. organization: Brigham and Women's Hospital, Harvard Medical School – sequence: 14 givenname: James D. surname: Berry fullname: Berry, James D. organization: Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School – sequence: 15 givenname: Roopali surname: Gandhi fullname: Gandhi, Roopali email: rgandhibwh@gmail.com organization: Brigham and Women's Hospital, Harvard Medical School
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/29466830$$D View this record in MEDLINE/PubMed
BookMark	eNp1kU9v1DAQxS1URLeFA18AReLSHtKO7cSOL0hoRQGpVQ-0EjfLcZzWlf8sdkK13x5Hu0VQwWkO83tvnt4coYMQg0HoLYYzDEDO_ZzPCMPAXqAVBsHrphXdAVoBbrqaUfH9EB3l_AAAuGP8FTokomGso7BCN-uYknFqsuGuyibNvvJWp5iCypUKQ6WdDVYrV21UUt5MJuXKhkr5bZxS3NxbXRW1SYXI2pkUs82v0ctRuWze7Ocxur34dLP-Ul9ef_66_nhZ64Y3rBYjbSgnPSWag-YdaSkmPWNkVLrVIzAiBs4ImAF6UZZctSP02JCBtMPQcnqMPux8N3PvzaBNmEoOuUnWq7SVUVn59ybYe3kXf8rSFRUYF4OTvUGKP2aTJ-lt1sY5FUycsyQAvCGsbWlB3z9DH-JcWnIL1TWiAWhFod79meh3lKfCC3C-A0rHOSczSm2n0n5cAlonMcjlpdIv15eXFsXpM8WT6b_YvfujdWb7f1Be3X7bKX4BhS-xMA
CitedBy_id	crossref_primary_10_1038_s41598_025_99206_2 crossref_primary_10_1093_hmg_ddac202 crossref_primary_10_1038_s41420_024_02283_x crossref_primary_10_1038_s41598_022_09572_4 crossref_primary_10_1242_jcs_258349 crossref_primary_10_3389_fgene_2019_00364 crossref_primary_10_1212_NXI_0000000000000491 crossref_primary_10_1038_s41598_022_05067_4 crossref_primary_10_1098_rsob_200116 crossref_primary_10_3390_biomedicines8020021 crossref_primary_10_1016_j_brainres_2022_148153 crossref_primary_10_1016_j_brainres_2018_12_016 crossref_primary_10_3389_fnins_2020_00354 crossref_primary_10_3390_ijms22041563 crossref_primary_10_1038_s41598_020_61246_1 crossref_primary_10_3390_jpm12050770 crossref_primary_10_1093_hmg_ddac250 crossref_primary_10_3390_ijms25137229 crossref_primary_10_1007_s00018_020_03619_3 crossref_primary_10_1016_j_neulet_2022_136918 crossref_primary_10_1097_MD_0000000000037470 crossref_primary_10_3390_ma15010126 crossref_primary_10_1002_mus_26141 crossref_primary_10_1093_braincomms_fcaf242 crossref_primary_10_1038_s41598_021_94734_z crossref_primary_10_1080_15622975_2021_2022757 crossref_primary_10_3390_cells11030572 crossref_primary_10_1016_j_pnpbp_2024_111130 crossref_primary_10_1002_acn3_51674 crossref_primary_10_3390_ijms23158487 crossref_primary_10_3390_biom11081220 crossref_primary_10_3390_ijms21124482 crossref_primary_10_3389_fneur_2019_00229 crossref_primary_10_3390_cells7110219 crossref_primary_10_3389_fnmol_2018_00288 crossref_primary_10_3389_fneur_2019_00186 crossref_primary_10_1080_19768354_2023_2180535 crossref_primary_10_3389_fnmol_2023_1123955 crossref_primary_10_3390_cells10051030 crossref_primary_10_3390_ijms22052737 crossref_primary_10_3390_biom14010047 crossref_primary_10_1002_mus_26370 crossref_primary_10_1007_s12035_023_03857_z crossref_primary_10_1186_s13578_021_00630_4 crossref_primary_10_1007_s10072_023_06860_3 crossref_primary_10_3390_ijms221910285 crossref_primary_10_1002_mds_27928 crossref_primary_10_1186_s12974_020_01822_4 crossref_primary_10_3389_fpsyt_2023_1160341 crossref_primary_10_1016_j_clineuro_2021_106883 crossref_primary_10_3390_ijms21103464 crossref_primary_10_4103_1673_5374_382226 crossref_primary_10_1016_j_exger_2020_111187 crossref_primary_10_1007_s12035_019_1615_1 crossref_primary_10_3389_fnmol_2024_1386735 crossref_primary_10_3390_biomedicines11051316 crossref_primary_10_3390_ijms20133148 crossref_primary_10_3389_fneur_2019_00291 crossref_primary_10_3390_ijms24054308 crossref_primary_10_3389_fnins_2023_1131758 crossref_primary_10_1371_journal_pone_0329321 crossref_primary_10_3390_clockssleep2030022 crossref_primary_10_3390_ijms21165699 crossref_primary_10_3390_cells10082043 crossref_primary_10_1038_s41598_020_71905_y crossref_primary_10_3390_ijms21051714 crossref_primary_10_1016_j_arr_2023_102126 crossref_primary_10_1111_1541_4337_12424 crossref_primary_10_1186_s13024_022_00515_1 crossref_primary_10_3389_fmed_2022_861960 crossref_primary_10_1111_jnc_15801 crossref_primary_10_3389_fneur_2019_00400 crossref_primary_10_3390_app10228274 crossref_primary_10_1007_s10072_020_04773_z crossref_primary_10_1159_000516928
Cites_doi	10.1073/pnas.1300894110 10.1016/j.omtn.2017.06.005 10.1002/jcp.25056 10.1038/nrneurol.2015.57 10.1056/NEJM199403033300901 10.1155/2016/5930621 10.20546/ijcmas.2016.501.020 10.1212/NXI.0000000000000267 10.1038/nn.3584 10.1016/S0022-510X(99)00210-5 10.1136/jnnp.2005.072660 10.1002/mus.24198 10.3109/17482960802635397 10.1073/pnas.1222361110 10.1016/S1474-4422(14)70129-2 10.3390/molecules19056891 10.1158/0008-5472.CAN-04-0496 10.1007/s12031-014-0471-8 10.1038/emboj.2012.319 10.1016/j.critrevonc.2015.10.003 10.3389/fncel.2014.00021 10.1016/j.brainres.2014.10.009 10.1016/S1474-4422(17)30115-1 10.1074/jbc.M110.144576 10.3389/fncel.2013.00216 10.1186/2051-5960-1-42 10.1016/j.biocel.2009.03.002 10.3389/fnagi.2017.00068 10.1038/nrm3838 10.1093/hmg/ddt261 10.1186/s13023-016-0531-y 10.1002/ana.22366 10.1126/science.1181046 10.1002/jnr.20443 10.1038/nrd.2016.246 10.5414/NP300889 10.1038/ng1725 10.1016/j.mcn.2015.12.008 10.1093/nar/gkv403 10.1212/NXG.0000000000000090 10.3389/fnmol.2016.00069 10.1016/j.clineuro.2011.11.026 10.1073/pnas.1112427109 10.1038/nrneurol.2013.203 10.1038/nmeth.3014
ContentType	Journal Article
Copyright	2018 Wiley Periodicals, Inc.
Copyright_xml	– notice: 2018 Wiley Periodicals, Inc.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TK 7TM 7TS 7U7 7U9 C1K H94 K9. NAPCQ 7X8 5PM
DOI	10.1002/mus.26106
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Physical Education Index Toxicology Abstracts Virology and AIDS Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Virology and AIDS Abstracts Toxicology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Neurosciences Abstracts Physical Education Index Environmental Sciences and Pollution Management MEDLINE - Academic
DatabaseTitleList	CrossRef MEDLINE - Academic MEDLINE Nursing & Allied Health Premium
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1097-4598
EndPage	269
ExternalDocumentID	PMC6103911 29466830 10_1002_mus_26106 MUS26106
Genre	article Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: National Center for Advancing Translational Sciences funderid: UH2/UH3 Grant TR000890 ; TR000890 – fundername: National Institutes of Health common – fundername: NCATS NIH HHS grantid: UH2 TR000890 – fundername: NCATS NIH HHS grantid: UH3 TR000890
GroupedDBID	--- -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 123 1CY 1L6 1OB 1OC 1ZS 31~ 33P 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AAQQT AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFNX AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHMBA AIACR AIDQK AIDYY AIQQE AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC FYBCS G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6M MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RX1 RYL SAMSI SUPJJ SV3 TEORI TUS TWZ UB1 V2E W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WVDHM WXI WXSBR X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~WT AAYXX CITATION O8X CGR CUY CVF ECM EIF NPM 7T5 7TK 7TM 7TS 7U7 7U9 C1K H94 K9. NAPCQ 7X8 5PM
ID	FETCH-LOGICAL-c4746-9f34372b32c70c7825312b662fac5cf0629d7620ed0b92537a5f0b1e2d25dd573
IEDL.DBID	DRFUL
ISICitedReferencesCount	83
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000445090300021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0148-639X 1097-4598
IngestDate	Tue Nov 04 02:00:01 EST 2025 Fri Jul 11 08:16:06 EDT 2025 Sat Nov 29 14:45:43 EST 2025 Mon Jul 21 05:59:50 EDT 2025 Tue Nov 18 21:48:25 EST 2025 Sat Nov 29 02:41:23 EST 2025 Tue Nov 11 03:14:50 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	2
Keywords	ALS longitudinal analysis microRNA disease comparisons serum biomarkers
Language	English
License	2018 Wiley Periodicals, Inc.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4746-9f34372b32c70c7825312b662fac5cf0629d7620ed0b92537a5f0b1e2d25dd573
Notes	National Center for Advancing Translational Sciences B. C. Healy has served on the scientific advisory board for Biogen and Worldwide Medical Biostatistics and has received research support from Merck Serono, Genzyme, Novartis, and Google Life Sciences. C. Diaz‐Cruz has received research support from Merck Serono and Google Life Sciences. T. Gholipour has received research support from Merck Serono, compensation as a reviewer from Boehringer Ingelheim, and spouse received compensation from Boehringer Ingelheim as a reviewer. B. I. Glanz has received research support from Merck Serono SA. P. Kivisakk has received research support from EMD Serono, Sanofi Genzyme, Verily Life Sciences. T. Chitnis served on clinical trial advisory boards for Novartis Pharmaceuticals and Genzyme‐Sanofi; consulted for Biogen Idec, Novartis, Genzyme‐Sanofi, Genentech Roche; and has received research support from EMD Serono, Novartis, Biogen, and Verily. H. L. Weiner has served on the scientific advisory board for Teva Pharmaceutical Industries, Biogen Idec, Novartis, Sanofi‐Aventis and has consulted for Therapix, Biogen, Novartis, Serono, Teva, and Sanofi. J. D Berry has consulted with Biogen, Denali Therapeutics and Neuraltus Pharmaceuticals and has received research support from Voyager Therapeutics and GSK, Cytokinetics, Brainstorm Cell Therapeutics, and Novartis. R. Gandhi has received research support from Novartis, Biogen, EMD Serono, and Sanofi. R. Raheja, K. Regev, M. A Mazzola, V. Beynon, F. Glehn, and A. Paul have no conflicts to report. Conflicts of Interest R. R. and K. R. contributed equally to this work. Funding This study was funded by National Institutes of Health funds via the (UH2/UH3 Grant TR000890). ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors contributed equally to this work.
ORCID	0000-0002-9897-4422 0000-0002-1004-7641
PMID	29466830
PQID	2084940059
PQPubID	1016420
PageCount	9
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_6103911 proquest_miscellaneous_2007426553 proquest_journals_2084940059 pubmed_primary_29466830 crossref_citationtrail_10_1002_mus_26106 crossref_primary_10_1002_mus_26106 wiley_primary_10_1002_mus_26106_MUS26106
PublicationCentury	2000
PublicationDate	August 2018
PublicationDateYYYYMMDD	2018-08-01
PublicationDate_xml	– month: 08 year: 2018 text: August 2018
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Rochester
PublicationTitle	Muscle & nerve
PublicationTitleAlternate	Muscle Nerve
PublicationYear	2018
Publisher	Wiley Subscription Services, Inc
Publisher_xml	– name: Wiley Subscription Services, Inc
References	2015; 56 1994; 330 2017; 8 2004; 64 2013; 1 2013; 22 2006; 77 2006; 38 2015; 11 2014; 49 2016; 98 2010; 285 2016; 2016 2005; 80 1999; 169 2016; 71 2013; 7 2017; 9 2012; 31 2016; 35 2013; 9 2012; 109 2016; 11 1994; 124 2016; 5 2010; 42 2016; 2 2009; 10 2016; 3 2017; 16 2015; 1607 2015; 43 2014; 15 2014; 13 2016; 231 2016 2014; 19 2013; 110 2014; 17 2011; 69 2012; 114 2014; 8 2016; 9 2014; 11 2009; 326 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 Granucci E (e_1_2_7_42_1) 2016 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 Brooks BR (e_1_2_7_22_1) 1994; 124 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_12_1 e_1_2_7_44_1 e_1_2_7_11_1 e_1_2_7_45_1 e_1_2_7_10_1 e_1_2_7_46_1 e_1_2_7_47_1 e_1_2_7_26_1 e_1_2_7_48_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_37_1 e_1_2_7_38_1 e_1_2_7_39_1 29665024 - Muscle Nerve. 2018 Aug;58(2):189-190 30383294 - Muscle Nerve. 2019 Jan;59(1):E2-E3 30383297 - Muscle Nerve. 2019 Jan;59(1):E3-E4
References_xml	– volume: 42 start-page: 1252 issue: 8 year: 2010 end-page: 1255 article-title: MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease publication-title: Int J Biochem Cell Biol – volume: 110 start-page: E756 issue: 8 year: 2013 end-page: E765 article-title: Intricate interplay between astrocytes and motor neurons in ALS publication-title: Proc Natl Acad Sci U S A – volume: 1 start-page: 42 year: 2013 article-title: Systemic dysregulation of TDP‐43 binding microRNAs in amyotrophic lateral sclerosis publication-title: Acta Neuropathol Commun – volume: 7 start-page: 216 year: 2013 article-title: Early gene expression changes in spinal cord from SOD1(G93A) amyotrophic lateral sclerosis animal model publication-title: Front Cell Neurosci – volume: 8 start-page: 21 year: 2014 article-title: Blood–CNS barrier impairment in ALS patients versus an animal model publication-title: Front Cell Neurosci – volume: 17 start-page: 17 issue: 1 year: 2014 end-page: 23 article-title: State of play in amyotrophic lateral sclerosis genetics publication-title: Nat Neurosci – volume: 9 start-page: 68 year: 2017 article-title: ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? publication-title: Front Aging Neurosci – volume: 69 start-page: 292 issue: 2 year: 2011 end-page: 302 article-title: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria publication-title: Ann Neurol – volume: 16 start-page: 505 issue: 7 year: 2017 end-page: 512 article-title: Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double‐blind, placebo‐controlled trial publication-title: Lancet Neurol – volume: 98 start-page: 12 year: 2016 end-page: 23 article-title: Exploring miRNA based approaches in cancer diagnostics and therapeutics publication-title: Crit Rev Oncol Hematol – volume: 109 start-page: 3347 issue: 9 year: 2012 end-page: 3352 article-title: TDP‐43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes publication-title: Proc Natl Acad Sci U S A – volume: 15 start-page: 509 issue: 8 year: 2014 end-page: 524 article-title: Regulation of microRNA biogenesis publication-title: Nat Rev Mol Cell Biol – volume: 231 start-page: 25 issue: 1 year: 2016 end-page: 30 article-title: MicroRNA as biomarkers and diagnostics publication-title: J Cell Physiol – volume: 114 start-page: 550 issue: 6 year: 2012 end-page: 554 article-title: Factors affecting the diagnostic delay in amyotrophic lateral sclerosis publication-title: Clin Neurol Neurosurg – volume: 31 start-page: 4502 issue: 24 year: 2012 end-page: 4510 article-title: FUS stimulates microRNA biogenesis by facilitating cotranscriptional Drosha recruitment publication-title: EMBO J – volume: 56 start-page: 102 issue: 1 year: 2015 end-page: 112 article-title: MicroRNAs as potential circulating biomarkers for amyotrophic lateral sclerosis publication-title: J Mol Neurosci – volume: 43 start-page: W460 issue: W1 year: 2015 end-page: W466 article-title: DIANA‐miRPath v3.0: deciphering microRNA function with experimental support publication-title: Nucleic Acids Res – volume: 16 start-page: 203 issue: 3 year: 2017 end-page: 222 article-title: MicroRNA therapeutics: towards a new era for the management of cancer and other diseases publication-title: Nat Rev Drug Discov – volume: 11 start-page: 809 issue: 8 year: 2014 end-page: 815 article-title: Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study publication-title: Nat Methods – volume: 285 start-page: 29223 issue: 38 year: 2010 end-page: 29230 article-title: MicroRNA 320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia publication-title: J Biol Chem – volume: 8 start-page: 132 year: 2017 end-page: 143 article-title: Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine publication-title: Mol Ther Nucleic Acids – volume: 71 start-page: 34 year: 2016 end-page: 45 article-title: Expression of microRNAs in human post‐mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms publication-title: Mol Cell Neurosci – volume: 2 start-page: e90 issue: 4 year: 2016 article-title: Trans‐pQTL study identifies immune crosstalk between Parkinson and Alzheimer loci publication-title: Neurol Genet – volume: 326 start-page: 1549 issue: 5959 year: 2009 end-page: 1554 article-title: MicroRNA‐206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice publication-title: Science – year: 2016 – volume: 2016 start-page: 5930621 year: 2016 article-title: Skeletal muscle remodelling as a function of disease progression in amyotrophic lateral sclerosis publication-title: Biomed Res Int – volume: 11 start-page: 148 issue: 1 year: 2016 article-title: Gene expression profiles and protein–protein interaction networks in amyotrophic lateral sclerosis patients with C9orf72 mutation publication-title: Orphanet J Rare Dis – volume: 1607 start-page: 75 year: 2015 end-page: 93 article-title: Genetic causes of amyotrophic lateral sclerosis: new genetic analysis methodologies entailing new opportunities and challenges publication-title: Brain Res – volume: 9 start-page: 617 issue: 11 year: 2013 end-page: 628 article-title: The epidemiology of ALS: a conspiracy of genes, environment and time publication-title: Nat Rev Neurol – volume: 80 start-page: 235 issue: 2 year: 2005 end-page: 246 article-title: Blood–brain barrier disruption highly induces aquaporin‐4 mRNA and protein in perivascular and parenchymal astrocytes: protective effect by estradiol treatment in ovariectomized animals publication-title: J Neurosci Res – volume: 11 start-page: 266 issue: 5 year: 2015 end-page: 279 article-title: Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era publication-title: Nat Rev Neurol – volume: 49 start-page: 786 issue: 6 year: 2014 end-page: 803 article-title: Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research publication-title: Muscle Nerve – volume: 110 start-page: 12066 issue: 29 year: 2013 end-page: 12071 article-title: MST1 functions as a key modulator of neurodegeneration in a mouse model of ALS publication-title: Proc Natl Acad Sci U S A – volume: 124 start-page: 96 issue: Suppl year: 1994 end-page: 107 article-title: El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors publication-title: J Neurol Sci – volume: 35 start-page: 22 issue: 1 year: 2016 end-page: 30 article-title: Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS publication-title: Clin Neuropathol – volume: 64 start-page: 5245 issue: 15 year: 2004 end-page: 5250 article-title: Normalization of real‐time quantitative reverse transcription‐PCR data: a model‐based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets publication-title: Cancer Res – volume: 169 start-page: 13 issue: 1–2 year: 1999 end-page: 21 article-title: The ALSFRS‐R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) publication-title: J Neurol Sci – volume: 13 start-page: 1127 issue: 11 year: 2014 end-page: 1138 article-title: Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? publication-title: Lancet Neurol – volume: 10 start-page: 418 issue: 5–6 year: 2009 end-page: 429 article-title: A genome‐wide analysis of brain DNA methylation identifies new candidate genes for sporadic amyotrophic lateral sclerosis publication-title: Amyotroph Lateral Scler – volume: 22 start-page: 4127 issue: 20 year: 2013 end-page: 4135 article-title: Method for widespread microRNA‐155 inhibition prolongs survival in ALS‐model mice publication-title: Hum Mol Genet – volume: 5 start-page: 221 issue: 1 year: 2016 end-page: 230 article-title: Downregulation of miR‐320 gene family memners in the peropheral blood of schizophrenia patients publication-title: Int J Curr Microbiol Appl Sci – volume: 19 start-page: 6891 issue: 5 year: 2014 end-page: 6910 article-title: Circulating miRNAs as biomarkers for neurodegenerative disorders publication-title: Molecules – volume: 9 start-page: 69 year: 2016 article-title: Aberration of miRNAs expression in leukocytes from sporadic amyotrophic lateral sclerosis publication-title: Front Mol Neurosci – volume: 38 start-page: 228 issue: 2 year: 2006 end-page: 233 article-title: The role of microRNA‐1 and microRNA‐133 in skeletal muscle proliferation and differentiation publication-title: Nat Genet – volume: 3 start-page: e267 issue: 5 year: 2016 article-title: Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis publication-title: Neurol Neuroimmunol Neuroinflamm – volume: 330 start-page: 585 issue: 9 year: 1994 end-page: 591 article-title: A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group publication-title: N Engl J Med – volume: 77 start-page: 390 issue: 3 year: 2006 end-page: 392 article-title: Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population publication-title: J Neurol Neurosurg Psychiatry – ident: e_1_2_7_41_1 doi: 10.1073/pnas.1300894110 – ident: e_1_2_7_18_1 doi: 10.1016/j.omtn.2017.06.005 – ident: e_1_2_7_20_1 doi: 10.1002/jcp.25056 – ident: e_1_2_7_2_1 doi: 10.1038/nrneurol.2015.57 – ident: e_1_2_7_3_1 doi: 10.1056/NEJM199403033300901 – ident: e_1_2_7_35_1 doi: 10.1155/2016/5930621 – ident: e_1_2_7_40_1 doi: 10.20546/ijcmas.2016.501.020 – volume: 124 start-page: 96 year: 1994 ident: e_1_2_7_22_1 article-title: El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors publication-title: J Neurol Sci – ident: e_1_2_7_26_1 doi: 10.1212/NXI.0000000000000267 – ident: e_1_2_7_10_1 doi: 10.1038/nn.3584 – ident: e_1_2_7_23_1 doi: 10.1016/S0022-510X(99)00210-5 – ident: e_1_2_7_24_1 doi: 10.1136/jnnp.2005.072660 – ident: e_1_2_7_11_1 doi: 10.1002/mus.24198 – ident: e_1_2_7_43_1 doi: 10.3109/17482960802635397 – ident: e_1_2_7_45_1 doi: 10.1073/pnas.1222361110 – ident: e_1_2_7_7_1 doi: 10.1016/S1474-4422(14)70129-2 – ident: e_1_2_7_16_1 doi: 10.3390/molecules19056891 – ident: e_1_2_7_48_1 doi: 10.1158/0008-5472.CAN-04-0496 – ident: e_1_2_7_17_1 doi: 10.1007/s12031-014-0471-8 – ident: e_1_2_7_14_1 doi: 10.1038/emboj.2012.319 – ident: e_1_2_7_21_1 doi: 10.1016/j.critrevonc.2015.10.003 – ident: e_1_2_7_39_1 doi: 10.3389/fncel.2014.00021 – ident: e_1_2_7_9_1 doi: 10.1016/j.brainres.2014.10.009 – ident: e_1_2_7_4_1 doi: 10.1016/S1474-4422(17)30115-1 – ident: e_1_2_7_37_1 doi: 10.1074/jbc.M110.144576 – ident: e_1_2_7_46_1 doi: 10.3389/fncel.2013.00216 – ident: e_1_2_7_13_1 doi: 10.1186/2051-5960-1-42 – ident: e_1_2_7_34_1 doi: 10.1016/j.biocel.2009.03.002 – ident: e_1_2_7_5_1 doi: 10.3389/fnagi.2017.00068 – ident: e_1_2_7_15_1 doi: 10.1038/nrm3838 – ident: e_1_2_7_32_1 doi: 10.1093/hmg/ddt261 – ident: e_1_2_7_44_1 doi: 10.1186/s13023-016-0531-y – ident: e_1_2_7_27_1 doi: 10.1002/ana.22366 – ident: e_1_2_7_36_1 doi: 10.1126/science.1181046 – ident: e_1_2_7_38_1 doi: 10.1002/jnr.20443 – ident: e_1_2_7_19_1 doi: 10.1038/nrd.2016.246 – ident: e_1_2_7_29_1 doi: 10.5414/NP300889 – ident: e_1_2_7_33_1 doi: 10.1038/ng1725 – ident: e_1_2_7_30_1 doi: 10.1016/j.mcn.2015.12.008 – ident: e_1_2_7_28_1 doi: 10.1093/nar/gkv403 – ident: e_1_2_7_25_1 doi: 10.1212/NXG.0000000000000090 – volume-title: Evaluating the Role of the Hippo pathway in the Onset and Disease Progression of the SOD1 Mouse Model of Anyotrophic Lateral Sclerosis year: 2016 ident: e_1_2_7_42_1 – ident: e_1_2_7_31_1 doi: 10.3389/fnmol.2016.00069 – ident: e_1_2_7_6_1 doi: 10.1016/j.clineuro.2011.11.026 – ident: e_1_2_7_12_1 doi: 10.1073/pnas.1112427109 – ident: e_1_2_7_8_1 doi: 10.1038/nrneurol.2013.203 – ident: e_1_2_7_47_1 doi: 10.1038/nmeth.3014 – reference: 30383294 - Muscle Nerve. 2019 Jan;59(1):E2-E3 – reference: 29665024 - Muscle Nerve. 2018 Aug;58(2):189-190 – reference: 30383297 - Muscle Nerve. 2019 Jan;59(1):E3-E4
SSID	ssj0001867
Score	2.5315762
Snippet	ABSTRACT Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease... Introduction : Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis... Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis.... Introduction: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis... Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and...
SourceID	pubmedcentral proquest pubmed crossref wiley
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	261
SubjectTerms	Adult ALS Alzheimer Disease - blood Alzheimer Disease - physiopathology Alzheimer's disease Amyotrophic lateral sclerosis Amyotrophic Lateral Sclerosis - blood Amyotrophic Lateral Sclerosis - physiopathology Biomarkers Biomarkers - blood Cohort Studies Cross-Sectional Studies Diagnosis disease comparisons Disease control Disease Progression Female Gene Expression Regulation Humans longitudinal analysis Longitudinal Studies Male Medical prognosis microRNA MicroRNAs - blood Middle Aged miRNA Multiple sclerosis Multiple Sclerosis - blood Multiple Sclerosis - physiopathology Muscles Neurodegenerative diseases Parameter identification Patients Ribonucleic acid RNA serum
Title	Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis
URI	https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmus.26106 https://www.ncbi.nlm.nih.gov/pubmed/29466830 https://www.proquest.com/docview/2084940059 https://www.proquest.com/docview/2007426553 https://pubmed.ncbi.nlm.nih.gov/PMC6103911
Volume	58
WOSCitedRecordID	wos000445090300021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library customDbUrl: eissn: 1097-4598 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001867 issn: 0148-639X databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VLUK98KZNKZVBHLiEeh0ndtQTKqw40ApBV9pb5NgOjdRkq80uEv-embxgVZCQuEWasfya8Uw8428AXkvLhUuUDbn2OpQF_rOmXsswMc6mkXFo83hbbEJdXOjFIv28A6fDW5gOH2K8cCPNaM9rUnCTNye_QEOrTfMW3X-C294VKLfxBHbff5nNP40HMWG1dRmMOkRDvBiAhbg4GRtvm6NbPubtVMnfXdjWBs0e_NfoH8L93vVk7zpZeQQ7vn4M98774PoTuDyjSh2UG1d_YyiZm4pVlK6HrRpmaseGV5SM8MIryqNpWFkzU_1YrlfLm6vSMmxNl1yswR5wwmXzFOazD5dnH8O-6EJopZK4U0VEobw8ElZxi_4DKqnIk0QUxsYW91KkDg9Q7h3PUyQqExc8n3rhROxcrKJnMKmXtT8A5pVKfOQKUSSplNJpKbi0aaGtyZX2LoA3w9pntkckp8IY11mHpSwyXKWsXaUAXo2sNx0Mx5-YjoYNzHpNRArXkoq_x2kAL0cy6hAFRkztl9SaHCmRxHEUwH6332MvggD4dcQDUFuSMDIQPvc2pS6vWpzuhMLs0ylOs5WEvw88O59_bT8O_531Oeyh76a7XMQjmKxXG_8C7trv67JZHcMdtdDHvUL8BCJQD2w
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED9NGwJeGN-EDTCIB17CXMeJHWkvaFAN0VYIWqlvUWI7LBJJp6ZF4r_nLl-jGkhIvEW6s_x157v4zr8DeC0NFzZSxufaaV_m-M8aOy39KLUmDlKLNo83xSbUbKaXy_jzHpz2b2FafIjhwo00ozmvScHpQvrkCjW03NZv0f8nvO0DiWKE8n3w_st4MRlOYgJra1MYtY-WeNkjC3FxMjTetUfXnMzruZK_-7CNERof_t_w78Kdzvlk71ppuQd7rroPN6ddeP0BzM-oVgdlx1XfGMrmtmQlJexhq5qllWX9O0pGiOElZdLUrKhYWv5cbdary4vCMGxN11ysxh5wxkX9EBbjD_Ozc78ru-AbqSTuVR5QMC8LhFHcoAeBaiqyKBJ5akKDuylii0cod5ZnMRJVGuY8GzlhRWhtqIJHsF-tKvcEmFMqcoHNRR7FUkqrpeDSxLk2aaa0sx686Rc_MR0mOZXG-J60aMoiwVVKmlXy4NXAetkCcfyJ6bjfwaTTRaRwLan8exh78HIgoxZRaCSt3IpakyslojAMPHjcbvjQiyAIfh1wD9SOKAwMhNC9S6mKiwapO6JA-2iE02xE4e8DT6aLr83H039nfQG3zufTSTL5OPt0BLfRk9NtZuIx7G_WW_cMbpgfm6JeP-_04hfr3xJ0
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9RAEB_KVYovWr9qtNVVfPAldm-zyW6gL9J6KLZH0R7cW0h2NzZgcsflTvC_dyZfetSC4FtgdtiPmdmd7Mz-BuCNNFzYSBmfa6d9meM_a-y09KPUmjhILZ55vCk2oaZTPZ_Hlztw0r-FafEhhgs3soxmvyYDd0ubH_9GDS039Tv0_wlve1dSEZkR7J59mczOh52YwNraFEbt40k875GFuDgemLfPoxtO5s1cyT992OYQmtz_v-Hvw73O-WTvW215ADuuegh7F114_RFcnVKtDsqOq74x1M1NyUpK2EOumqWVZf07SkaI4SVl0tSsqFha_lysV4vldWEYctM1F6uxB5xxUT-G2eTD1elHvyu74BupJMoqDyiYlwXCKG7Qg0AzFVkUiTw1oUFpitjiFsqd5VmMRJWGOc_GTlgRWhuq4AmMqkXlngJzSkUusLnIo1hKabUUXJo41ybNlHbWg7f94iemwySn0hjfkxZNWSS4SkmzSh68HpouWyCOvzU67CWYdLaIFK4llX8PYw9eDWS0IgqNpJVbEDe5UiIKw8CDg1bgQy-CIPh1wD1QW6owNCCE7m1KVVw3SN0RBdrHY5xmowq3Dzy5mH1tPp79e9OXsHd5NknOP00_P4e76MjpNjHxEEbr1cYdwR3zY13UqxedWfwCXmcR7w
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Correlating+serum+micrornas+and+clinical+parameters+in+amyotrophic+lateral+sclerosis&rft.jtitle=Muscle+%26+nerve&rft.au=Raheja%2C+Radhika&rft.au=Regev%2C+Keren&rft.au=Healy%2C+Brian+C.&rft.au=Mazzola%2C+Maria+Antonietta&rft.date=2018-08-01&rft.issn=0148-639X&rft.eissn=1097-4598&rft.volume=58&rft.issue=2&rft.spage=261&rft.epage=269&rft_id=info:doi/10.1002%2Fmus.26106&rft.externalDBID=10.1002%252Fmus.26106&rft.externalDocID=MUS26106
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0148-639X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0148-639X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0148-639X&client=summon